Oral immediate-release nifedipine versus parenteral hydralazine for controlling severe hypertension in pregnancy: a double-blind randomized trial

AYO OKWUOSA0 个研究点目标入组 70 人开始时间: 2019年6月3日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•a. All pregnant women with systolic blood pressure of 160mmHg and above, and/or diastolic blood pressure of 110mmHg and above, that persists after 15 minutes.
•b.The gestational age of the pregnancy must be beyond the age of viability, which is 28 weeks in the study setting.
•c.All pregnant women who give their consent.

•a)All patients who refused to give consent for the study.
•b)Any pregnant woman with severe hypertension and seizures, and/ or coma (eclampsia).
•c)Any pregnant woman with signs of imminent eclampsia such as: severe headache, blurring of visions, epigastric pain, or reduced urinary output.
•d)Any pregnant woman with severe hypertension complicated by abruptio placentae, or cerebrovascular accident.
•e)Any pregnant woman with severe hypertension and already established fetal complications, such as: intrauterine growth restriction, or intrauterine fetal death.
•f)All pregnant women with other co-morbidities such as; asthma, cardiac disease, diabetes mellitus, and other medical disorders in pregnancy.
•g) Any pregnant woman with prior adverse drug reaction to hydralazine and nifedipine.
•h)Any pregnant woman with a history of use of any antihypertensive medication within 12 hours of recruitment.

发起方

AYO OKWUOSA